E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The efficacy and safety of ibuprofen plus hyoscine butylbromide for pain management due to primary dysmenorrhea will be investigated. Primary dysmenorrhea is the most common gynecological complaint in reproductive women. It is characterized by painful uterine contraction or menstrual cramps, occurring during menstruation without pelvic pathologies. Pain usually occurs intensely on the first or second day or the first 24–36 hours of menstruation. |
|
E.1.1.1 | Medical condition in easily understood language |
The efficacy and safety of ibuprofen plus hyoscine butylbromide for pain management due to primary dysmenorrhea will be investigated. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of a combination of ibuprofen plus hyoscine butylbromide as compared to ibuprofen alone and hyoscine butylbromide alone for the management of pain due to primary dysmenorrhea. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the tolerability of ibuprofen plus hyoscine butylbromide |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
[1]Female patients ≥18 and ≤40 years of age [2]Patients with a history of primary dysmenorrhea [3]Patients with moderate to severe pain in at least 5 of the last 6 menstrual cycles [4]Patients willing and able (e.g., mental and physical condition) to participate in all aspects of the study as evidenced by providing signed written informed consent
|
|
E.4 | Principal exclusion criteria |
[1]History of hypersensitivity or intolerance to the active substances or any of the excipients of the study medication [2]History of hypersensitivity reactions (e.g., asthma, urticaria, angioedema or rhinitis) after taking other NSAIDs (e.g., acetylsalicylic acid or similar) [3]Any condition which might cause secondary dysmenorrhoea (e.g., endometriosis, salpingitis, adhesions) [4]Other likely causes of abdominal pain (e.g., gastric or peptic ulcer, inflammatory bowel disease, leiomyoma, pelvic inflammatory disease) [5]History of gastrointestinal bleeding [6]Conditions involving an increased tendency to bleeding [7]History of frequent dyspepsia, heartburn or indigestion [8]Severe heart failure (NYHA Class IV), hepatic failure and renal failure [9]Any of the following conditions: a)untreated narrow angle glaucoma, b)gastric outlet obstruction, c)intestinal atony, d)tachycardia, e)mechanical stenosis of the gastrointestinal tract, myasthenia gravis, f)megacolon [10]History of significant disease deemed by the investigator to render the patients unsuitable for inclusion [11]Concomitant major depression [12]Concomitant condition that may interfere with the absorption, distribution, metabolism, or excretion of the study medication [13]Previous (within 7 days before first study drug administration) intake or administration of analgesic, anti-inflammatory, antispasmodic or other therapy for dysmenorrhoea [14]Previous (within 7 days before first study drug administration) intake or administration of medications that might confound the assessment of pain relief, such as psychotropic drugs, antidepressants, sedative-hypnotics, NSAIDs, muscle relaxants* [15]Intake of oral contraceptives during the last 2 menstrual cycles preceding the trial [16]Administration of hormonal contraceptive devices during the last 2 menstrual cycles preceding the trial [17]Administration of long-acting depot contraceptives within the last 6 months preceding the trial [18]Patient is currently enrolled in, or has completed less than 30 days before the screening examination of the present trial another clinical trial with an investigational drug [19]Previous enrolment in this study [20]Pregnant or breast-feeding women [21]Women of childbearing potential unable or unwilling to undergo pregnancy tests and to practice adequate contraceptive measures. Reliable methods for women during the trial are: a)combination of 2 barrier methods: female/male condoms, diaphragms, spermicides b)surgical intervention (e.g., tubal ligation), c)non-hormonal intrauterine device (IUD) d)sexual abstinence [22]Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the study [23]Alcohol/drug dependence or abuse (excluding tobacco abuse) [24]Unreliability or lack of cooperation [25]Any other condition of the patient (e.g., serious or unstable medical or psychological condition, acute psychosis) that in the opinion of the investigator may compromise evaluation of the study treatment or may jeopardize patient’s safety, compliance or adherence to protocol requirements |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Area under the curve from 0 to 4 hours after each of the first two doses (AUC0-4h) for the pain intensity differences (pre-dose - post dose) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
before intake as well as 10, 20, 30, 40, 50, 60 minutes and 1.5, 2, 3, 4 hours after each of the first 2 doses of study medication |
|
E.5.2 | Secondary end point(s) |
• Area under the curve from 0 to 2 hours after each of the first two doses for the pain intensity differences (pre-dose - post dose) • Area under the curve from 0 to 6 hours after each of the first two doses for the pain intensity differences (pre-dose - post dose) • Partial areas under the curve: 0 to 1 hour, 1 to 2 hours, and 2 to 6 hours after each of the first two doses for the pain intensity differences (pre-dose - post dose) • Pain intensity differences (pre-dose - post dose) at each of the pre-defined points in time: 10, 20, 30, 40, 50, 60 minutes and 1.5, 2, 3, 4, 5, and 6 hours after each of the first two doses of study medication • Percentage of patients who reach at least 30% reduction in pain intensity after each of the first two doses • Percentage of patients who reach at least 50% reduction in pain intensity after each of the first two doses • Time to at least 30% reduction in pain intensity after each of the first two doses • Time to at least 50% reduction in pain intensity after each of the first two doses • Number of patients using rescue medication within the first 2 hours post dose • Number of patients using rescue medication within the entire duration of treatment • Patient’s global ratings of pain relief |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• from 0 to 2 hours after each of the first two doses • from 0 to 6 hours after each of the first two doses • 0 to 1 hour, 1 to 2 hours, and 2 to 6 hours after each of the first two doses • 10, 20, 30, 40, 50, 60 minutes and 1.5, 2, 3, 4, 5, and 6 hours after each of the first two doses of study medication • after each of the first two doses • within the first 2 hours post dose • entire duration of treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The last visit and end of the trial is the final examination, performed up to 7 days after day 1 in last cycle.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |